CareDx, Inc. Stock News

CareDx is a promising candidate for the Bioreactor growth portfolio due to its leadership in transplant diagnostics and significant growth potential despite previous concerns. The company has shown strong revenue growth, with Q3 2023 revenue up 23% YoY, and maintains a robust balance sheet with $241M in cash and no debt. Key risks include potential slow adoption by transplant centers, competiti...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conf...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx will partner with TC BioPharm to perform pharmacokinetic analysis using its A...

EDINBURGH, Scotland , Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a partnership with CareDx, Inc. (NASDAQ: CDNA) The Transplant Company™ who will perform pharmacokinetic analysis using it...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Jefferies London Heal...

CareDx, Inc (NASDAQ:CDNA ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Bill Bonello - Craig-Hallum Mark Massaro - BTIG Brandon Couillard - Wells Fargo Yi Chen - H.C. Wainwright Mason Carrico - Stephens In...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Total revenue of $82.9 million increased 23% year-over-year Testing Services volume of 44,600 tests increased 16% year-over-year GAAP net loss of $7.4 million, non-GAAP net income of $8.0 million, and positive ...

NEW ORLEANS, LA / ACCESSWIRE / October 25, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.